You are here

  • Home
  • Archive
  • Volume 79, Issue Suppl 1
  • THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY

Article info

Article menu

Download PDFPDF

Scientific Abstracts
Poster Presentations
Thursday, 04 June 2020
Scleroderma, myositis and related syndromes
THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY
Free

Authors

Citation

Lafyatis R, Spiera R, Domsic R, et al
THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY
Annals of the Rheumatic Diseases 2020;79:394-395.

Publication history

  • First published June 2, 2020.
Online issue publication 
January 08, 2022

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.